Edition:
United States

Eli Lilly and Co (LLY.N)

LLY.N on New York Stock Exchange

78.05USD
4:02pm EDT
Change (% chg)

$-0.29 (-0.37%)
Prev Close
$78.34
Open
$78.12
Day's High
$78.28
Day's Low
$77.72
Volume
606,223
Avg. Vol
1,083,920
52-wk High
$86.71
52-wk Low
$64.25

Select another date:

Thu, May 18 2017

BRIEF-United Therapeutics says it entered into first amendment to license agreement with Eli Lilly and company

* United Therapeutics Corp - on May 17, 2017, co entered into first amendment to license agreement with Eli Lilly and company

BRIEF-Eli Lilly and Co files for potential three-part notes offering

* Eli Lilly and Co files for potential three-part notes offering; size undisclosed Source text :(http://bit.ly/2qIKWbH) Further company coverage:

BRIEF-Eli Lilly and Co sets Q2 2017 dividend of $0.52 per share

* Sets quarterly dividend of $0.52 per share Source text for Eikon: Further company coverage:

BRIEF-Eli Lilly says Lilly Endowment Inc reports open market sale of 210,000 of stock

* Lilly Endowment Inc reports open market sale of 210,000 of co's common stock on march 30 at $84.674 per share - SEC filing Source text (http://bit.ly/2nrnkag) Further company coverage:

BRIEF-Intelgenx Technologies says Eli Lilly granted Versafilm exclusive license for tadalafil film product under erectile dysfunction dosing patent

* Intelgenx Technologies- Eli Lilly granted Intelgenx' Versafilm exclusive license for tadalafil film product under erectile dysfunction dosing patent

BRIEF-Eli Lilly and Co says CEO John Lechleiter's 2016 total compensation was $18.4 mln

* CEO John C. Lechleiter's 2016 total compensation was $18.4 million versus $16.6 million in 2015

Federal Circuit revives Cialis patent claims against Lilly

By Jan Wolfe The U.S. Court of Appeals for the Federal Circuit has breathed new life into a research institute’s claims that Eli Lilly and Co’s erectile dysfunction drug Cialis infringes on one of its patents.

AARP, Eli Lilly support Sanofi, Regeneron in cholesterol drug fight

Seniors' advocacy group AARP and drugmaker Eli Lilly & Co on Thursday urged a federal appeals court to overturn a court order barring sales of Sanofi SA and Regeneron Pharmaceuticals Inc's cholesterol drug Praluent.

BRIEF-Lilly says provisions included in legislation to repeal Affordable Care Act could adversely affect results

* Provisions included in legislation repealing, replacing affordable care act could have material adverse effect on consolidated results, cash flows Source text - (http://bit.ly/2kIQynP) Further company coverage:

BRIEF-Eli Lilly says additional results from pivotal ra-beam study published in New England Journal of Medicine

* Eli Lilly - additional results from pivotal ra-beam study published in New England Journal of Medicine

Select another date:

More From Around the Web